Key Points
- Director Steve Elms purchased 7,000 shares at $15.67 each (about $109,690), increasing his holdings to 2,038,730 shares—a 0.34% rise in his ownership.
- ADMA reported quarterly EPS of $0.20 (in line with estimates) on $139.16M in revenue, up 18.4% year‑over‑year, with a 37.5% ROE, 28.8% net margin, a $3.77B market cap and a 26.35 P/E.
- Institutional investors own 75.68% of the stock with recent inflows from firms like RBC and UBS, and analysts show a consensus Buy rating with an average price target of $32.00.
ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) Director Steve Elms bought 7,000 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director owned 2,038,730 shares of the company's stock, valued at $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
ADMA Biologics Stock Performance
Shares of ADMA stock opened at $15.81 on Tuesday. ADMA Biologics Inc has a 1-year low of $13.76 and a 1-year high of $25.67. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 26.35 and a beta of 0.51. The stock's fifty day simple moving average is $16.86 and its 200-day simple moving average is $16.76.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period in the prior year, the business earned $0.46 EPS. The business's revenue for the quarter was up 18.4% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada lifted its holdings in ADMA Biologics by 112.7% in the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company's stock worth $1,903,000 after purchasing an additional 50,801 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in ADMA Biologics during the first quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in ADMA Biologics by 59.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company's stock valued at $16,201,000 after purchasing an additional 305,064 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of ADMA Biologics by 108.5% in the second quarter. Envestnet Asset Management Inc. now owns 143,229 shares of the biotechnology company's stock valued at $2,608,000 after purchasing an additional 74,543 shares during the period. Finally, Bank of Montreal Can lifted its stake in shares of ADMA Biologics by 18.1% in the second quarter. Bank of Montreal Can now owns 42,269 shares of the biotechnology company's stock worth $770,000 after buying an additional 6,466 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Analysts Set New Price Targets
Several research firms recently commented on ADMA. Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Wall Street Zen raised shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Zacks Research raised shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of "Buy" and an average price target of $32.00.
Get Our Latest Stock Analysis on ADMA
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
